Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer to provide breast cancer drug for free while awaiting NHS approval

Pfizer to provide breast cancer drug for free while awaiting NHS approval

5th May 2017

Pfizer has announced that it will be providing a breast cancer drug that is awaiting NHS approval free of charge to UK patients.

The company is offering palbociclib for free to women with metastatic breast cancer as an interim measure while the National Institute for Health and Care Excellence's (NICE's) appraisal process remains ongoing.

Clinical trial data has shown that palbociclib, when used in combination with letrozole, can increase progression-free survival to a median 24.8 months, compared with 14.5 months for letrozole alone.

NICE provisionally ruled in February that palbociclib would not be routinely funded on the NHS in England, but the final appraisal process has been paused to give Pfizer an opportunity to submit additional supporting data.

A spokeswoman for Pfizer said: "Pfizer believes women with metastatic breast cancer deserve access as soon as possible to this innovative medicine that has been shown to significantly increase progression-free survival."

The free programme will run for a maximum of five months, closing six weeks after ICE issues final guidance on the drug, or on September 30th, whichever is earlier.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801835511-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.